

CIRM Funded Clinical Trials

Genetic Re-programming of Stem Cells to Fight Cancer

Disease Area:	Melanoma, Skin cancer
Investigator:	Antoni Ribas
Institution:	University of California, Los Angeles
CIRM Grant:	DR2A-05309
Award Value:	\$19,875,776
Trial Sponsor:	University of California, Los Angeles
Trial Stage:	Phase 1
Trial Status:	Recruiting
Targeted Enrollment:	12
ClinicalTrials.gov ID:	NCT03240861



Antoni Ribas

Details:

There are few options for patients whose cancers have metastasized due to resistance to current therapies. This team is using gene editing technology to modify a patient's own immune system cells and blood-forming stem cells with the aim of creating a continuous supply of immune cells that can recognize and attack hard-to-treat cancers.

Design:

Single dose.

Goal:

Primary: Safety and feasibility. Secondary: Persistence of gene-marked anti-cancer immune cells

Updates:

Enrolling.

News Releases:

UCLA opens first engineered blood stem cell clinical trial for cancers with the NY-ESO-1 tumor marker

[Contact Trial Sponsor](#)